Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Eur J Med Chem
; 229: 114009, 2022 Feb 05.
Article
en En
| MEDLINE
| ID: mdl-34839996
ABSTRACT
Bruton's tyrosine kinase (BTK) regulates multiple important signaling pathways and plays a key role in the proliferation, survival, and differentiation of B-lineage cells and myeloid cells. BTK is a promising target for the treatment of hematologic malignancies. Ibrutinib, the first-generation BTK inhibitor, was approved to treat several B-cell malignancies. Despite the remarkable potency and efficacy of ibrutinib against various lymphomas and leukemias in the clinics, there are also some clinical limitations, such as off-target toxicities and primary/acquired drug resistance. As strategies to overcome these challenges, second- and third-generation BTK inhibitors, BTK-PROTACs, as well as combination therapies have been explored. In this review, we summarize clinical developments of the first-, second- and third-generation BTK inhibitors, as well as recent advances in BTK-PROTACs and ibrutinib-based combination therapies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piperidinas
/
Adenina
/
Inhibidores de Proteínas Quinasas
/
Agammaglobulinemia Tirosina Quinasa
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article